Schrodinger Inc (SDGR) FinancialsSDGRSchrodinger Inc

Schrodinger Inc (SDGR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Software contributions, accounting for 105.0% of total sales, equivalent to $61.81M. Other significant revenue streams include Drug discovery services and Hosted software. Understanding this composition is critical for investors evaluating how SDGR navigates market cycles within the Software industry.

Evaluating the bottom line, Schrodinger Inc maintains a gross margin of 55.07%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -70.55%, while the net margin is 10.15%. These profitability ratios, combined with a Return on Equity (ROE) of -16.18%, provide a clear picture of how effectively SDGR converts its operational activities into shareholder value.

In the context of the broader market, SDGR competes directly with industry leaders such as INNV and BBAI. With a market capitalization of $1.53B, it holds a leading position in the sector. When comparing efficiency, SDGR's gross margin of 55.07% stands against INNV's 22.27% and BBAI's 32.79%. Such benchmarking helps identify whether Schrodinger Inc is trading at a premium or discount relative to its financial performance.

In Q2 2026, Schrodinger reported a net income of $6 million and a gross margin of 55.07%, indicating improving profitability. The company also raised its drug discovery revenue guidance to between $65 million and $75 million for 2026, reflecting strong growth potential.